Herbert et al., 2017 - Google Patents
Antibodies from a human survivor define sites of vulnerability for broad protection against ebolavirusesHerbert et al., 2017
View PDF- Document ID
- 1524813448410638515
- Author
- Herbert A
- Wec A
- Murin C
- Nyakatura E
- Abelson D
- Fels J
- He S
- James R
- De La Vega M
- Bakken R
- Goodwin E
- Turner H
- Jangra R
- Zeitlin L
- Qiu X
- Lai J
- Walker L
- Ward A
- Dye J
- Chandran K
- Publication year
External Links
Snippet
Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wec et al. | Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses | |
| Zhao et al. | Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability | |
| Flyak et al. | Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection | |
| Widjaja et al. | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein | |
| Holtsberg et al. | Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses | |
| Gilchuk et al. | Pan-ebolavirus protective therapy by two multifunctional human antibodies | |
| US12162926B2 (en) | Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins | |
| US11084869B2 (en) | Antibody-mediated neutralization of Marburg virus | |
| Herbert et al. | Development of an antibody cocktail for treatment of Sudan virus infection | |
| Durie et al. | Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus | |
| WO2018039514A1 (en) | Antibody-mediated neutralization of ebolaviruses | |
| US12209117B2 (en) | Monoclonal antibodies and cocktails for treatment of Ebola infections | |
| Wang et al. | Prominent neutralizing antibody response targeting the ebolavirus glycoprotein subunit interface elicited by immunization | |
| Herbert et al. | Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses | |
| WO2021258190A1 (en) | Pan-ebolavirus monoclonal antibody | |
| Sajadi et al. | A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV | |
| Gilchuk et al. | Protective pan-ebolavirus combination therapy by two multifunctional human antibodies | |
| Perrett | Sugar, Ice, and Everything (Not So) Nice: Structural Interrogation of the Lassa Glycoprotein Complex and Its Recognition by the Humoral Immune System | |
| Wirchnianski | Broadening Therapeutic Antibodies against Filoviruses through Bispecific Engineering | |
| Zhao et al. | Broad Neutralization of Ebolaviruses via a Fusion Loop Epitope Elicited by Immunization | |
| Wu² et al. | convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and | |
| Flyak | The Analysis of the Human Antibody Response to Filovirus Infection | |
| EP3583122A1 (en) | Monoclonal antibodies and cocktails for treatment of ebola infections | |
| EP3548075A1 (en) | Arenavirus monoclonal antibodies and uses |